Murad Joana M, Graber David J, Sentman Charles L
Celdara Medical LLC, Lebanon, NH, 16 Cavendish Ct Suite 240, Lebanon, NH 03766, USA.
Center for Synthetic Immunity and Department of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, One Medical Center Dr., Lebanon, NH 03765, USA.
Best Pract Res Clin Haematol. 2018 Jun;31(2):176-183. doi: 10.1016/j.beha.2018.03.003. Epub 2018 Mar 27.
Chimeric antigen receptors (CAR)-T cell therapy has recently made promising advances towards treatment of B-cell malignancies. This approach makes use of an antibody-derived single chain variable fragment (scFv)-based CAR to target the CD19 antigen. Currently scFvs are the most common strategy for creation of CARs, but tumor cells can also be targeted using non-antibody based approaches with designs focused on the interaction between natural receptors and their ligands. This emerging strategy has been used in unique ways to target multiple tumor types, including solid and haematological malignancies. In this review, we will highlight the performance of receptor-ligand combinations as designs for CARs to treat cancer, with a particular focus on haematologic malignancies.
嵌合抗原受体（CAR）-T细胞疗法最近在治疗B细胞恶性肿瘤方面取得了令人鼓舞的进展。这种方法利用基于抗体衍生的单链可变片段（scFv）的CAR来靶向CD19抗原。目前，scFv是创建CAR的最常用策略，但肿瘤细胞也可以使用基于非抗体的方法进行靶向，其设计重点是天然受体与其配体之间的相互作用。这种新兴策略已被以独特方式用于靶向多种肿瘤类型，包括实体瘤和血液系统恶性肿瘤。在本综述中，我们将重点介绍受体-配体组合作为治疗癌症的CAR设计的性能，特别关注血液系统恶性肿瘤。
